Kymera Therapeutics (KYMR) EBITDA (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly EBITDA of -$84.2 million for Q1 2026, down 13.07% year-over-year from -$96.8 million in Q1 2025, and up 14.04% quarter-over-quarter from -$97.9 million in Q4 2025.
Kymera Therapeutics (KYMR) EBITDA (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported EBITDA for 8 consecutive years, with -$84.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 13.07% year-over-year to -$84.2 million; the TTM figure through Mar 2026 stood at -$359.1 million (down 29.08% YoY), while the FY2025 annual figure was -$349.4 million, down 33.54% from the prior year.
- EBITDA advanced to -$84.2 million in Q1 2026 per KYMR's latest filing, from -$97.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$19.3 million in Q4 2023 and bottomed at -$97.9 million in Q4 2025.
- Historically, EBITDA has averaged -$60.1 million across 5 years, with a median of -$57.5 million in 2023.
- Annual changes were most pronounced in 2023 — EBITDA surged 50.01% — and 2024, when it slumped 318.16%.
- Kymera Therapeutics' EBITDA stood at -$38.6 million in 2022, then soared by 50.01% to -$19.3 million in 2023, then plunged by 318.16% to -$80.8 million in 2024, then dropped by 21.23% to -$97.9 million in 2025, then climbed by 14.04% to -$84.2 million in 2026.
- Business Quant data shows KYMR's EBITDA at -$84.2 million in Q1 2026, -$97.9 million in Q4 2025, and -$92.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -75.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.61 Mn |
| Mar 31, 2026 | -84.15 Mn |
| Dec 31, 2025 | -97.90 Mn |
| Sep 30, 2025 | -92.52 Mn |
| Jun 30, 2025 | -84.56 Mn |
| Mar 31, 2025 | -74.43 Mn |
| Dec 31, 2024 | -80.76 Mn |
| Sep 30, 2024 | -72.12 Mn |
| Jun 30, 2024 | -50.93 Mn |
| Mar 31, 2024 | -57.83 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -57.51 Mn |
| Jun 30, 2023 | -43.38 Mn |
| Mar 31, 2023 | -45.33 Mn |
| Dec 31, 2022 | -38.63 Mn |
| Sep 30, 2022 | -44.88 Mn |
| Jun 30, 2022 | -40.81 Mn |
| Mar 31, 2022 | -36.93 Mn |
| Dec 31, 2021 | -33.99 Mn |
| Sep 30, 2021 | -28.64 Mn |